Description
Activation of Pyruvate Kinase M2 as a Novel Therapy for Chemotherapy-Induced Cardiotoxicity
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02017-04-01$799,425
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2017-04-01(start date) | $799,425 | — | Activation of Pyruvate Kinase M2 as a Novel Therapy for Chemotherapy-Induced Cardiotoxicity |
Related records · 3
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 110_2026_2027_Q1_3379 | Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada · Discovery Research | $195,000 | FY2027 |
| 236-2023-2024-Q1-01337 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $1,147,500 | FY2024 |
| 236-2022-2023-Q1-00385 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $956,250 | FY2023 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2017-2018-Q1-00621 · retrieved 2026-11-14.